Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review

Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectables for the treatment of opioid dependence, and buprenorphine-based injectable suspension, for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses products for substance use disorder; and cannabis disorder. Indivior offers products in various formulations, including tablets, transmucosal films, nasal sprays, and injectables. It offers its products across various countries globally. Indivior is headquartered in North Chesterfield, Virginia, the US.

Indivior Plc Key Recent Developments

Apr 25,2024: Indivior : 1ST Quater Results
Mar 21,2024: Indivior Plc : Appointment of Independent Non-executive Director
Feb 22,2024: Indivior Plc : Final Results
Feb 22,2024: Indivior Announces Q4 / FY 2023 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Indivior Plc - Key Facts
Indivior Plc - Key Employees
Indivior Plc - Key Employee Biographies
Indivior Plc - Major Products and Services
Indivior Plc - History
Indivior Plc - Company Statement
Indivior Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Indivior Plc - Business Description
Product Category: Perseris
Overview
Performance
Product Category: Sublingual/Other
Overview
Performance
Product Category: Sublocade
Overview
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
R&D Overview
Indivior Plc - Corporate Strategy
Indivior Plc - SWOT Analysis
SWOT Analysis - Overview
Indivior Plc - Strengths
Indivior Plc - Weaknesses
Indivior Plc - Opportunities
Indivior Plc - Threats
Indivior Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Indivior Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 25, 2024: Indivior : 1ST Quater Results
Mar 21, 2024: Indivior Plc : Appointment of Independent Non-executive Director
Feb 22, 2024: Indivior Plc : Final Results
Feb 22, 2024: Indivior Announces Q4 / FY 2023 Financial Results
Dec 20, 2023: Indivior Settles Patent Dispute with Teva Subsidiary Actavis
Nov 09, 2023: Indivior Announces Third Quarter Results
Nov 09, 2023: Indivior Announces Q3 2023 Financial Results
Nov 09, 2023: Indivior PLC - Appointment of Independent Non-Executive Director
Oct 23, 2023: Indivior Reaches Agreement With Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results
Sep 29, 2023: Indivior Announces Board Committee Changes
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Indivior Plc, Key Facts
Indivior Plc, Key Employees
Indivior Plc, Key Employee Biographies
Indivior Plc, Major Products and Services
Indivior Plc, History
Indivior Plc, Other Locations
Indivior Plc, Subsidiaries
Indivior Plc, Key Competitors
Indivior Plc, Ratios based on current share price
Indivior Plc, Annual Ratios
Indivior Plc, Annual Ratios (Cont...1)
Indivior Plc, Annual Ratios (Cont...2)
Indivior Plc, Interim Ratios
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Indivior Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Indivior Plc, Performance Chart (2019 - 2023)
Indivior Plc, Ratio Charts
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Indivior Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings